Last reviewed · How we verify
Ritlecitinib 50 mg (ritlecitinib-50-mg)
At a glance
| Generic name | ritlecitinib-50-mg |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Approved indications
Common side effects
- Abdominal distension
- Dyspepsia
- Escherichia urinary tract infection
- Pain in extremity
- Gastroenteritis viral
- Procedural dizziness
Key clinical trials
- A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 (PHASE3)
- A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo (PHASE3)
- A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. (PHASE2)
- A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata (PHASE3)
- A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo (PHASE3)
- PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA (PHASE2)
- A Target Occupancy Study With Ritlecitinib. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ritlecitinib 50 mg CI brief — competitive landscape report
- Ritlecitinib 50 mg updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI